Funding

GEN's Editor-in-Chief John Sterling outlines his picks for the top ten "must attend" breakout sessions at the 2011 BIO International Convention.

 John Carroll, editor of Fierce Biotech, shares what he won't miss at the 2011 BIO International Convention.

As Japan works to stabilize the crippled nuclear power plant in Fukushima, people are stocking up on potassium iodide tablets – one of the only drugs available to block the body's absorption of some radioactive materials.

The Massachusetts Life Sciences Center, which is tasked with administering the $1 billion state's life sciences initiative, has awarded five loans to start up companies, totaling $3.75 million.

Budget victories will help biotechnology in the Commonwealth

Industry leaders point out that biotech-enabled advanced biofuels spur job growth and reduce U.S. dependence on imported oil.

Dr. Ferstenberg discusses an innovative program to guide small emerging biotech companies and how women in biotech can accelerate their leadership within the industry.

Dr. Ferstenberg discusses an innovative program to guide small emerging biotech companies and how women in biotech can accelerate their leadership within the industry. 

New listing requirements for proposed market would give more biotech companies option of going public.

The government’s Qualifying Therapeutic Discovery Project Program is doing what it was intended to do, according to a recent survey of senior executives at small biotechnology companies.

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year’s BIO International Convention.  Created in partnership with BIO, the publication explores the diverse economic regions of the world, highlighting success stories, policy achievements, cutting-edge science and the unique challenges that lie ahead. This year’s report focuses on BRIC (Brazil, Russia, India and China) country efforts to build local biotechnology hubs. 

The 12th Annual BIO Investor Forum featured exciting panels, partnering meetings and more!

July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country.
December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of implementing policies that will spur job growth through capital formation while protecting investors.  
May 17 2011
BIO encourages Congress to support advanced biofuels and biobased products programs and initiatives during consideration of the Fiscal Year 2012 Energy & Water Appropriations bill. Industrial biotechnology is the key enabling technology that is causing a dramatic paradigm shift in the production of fuels and chemicals. By building modern biorefineries and using industrial biotechnology our nation could significantly reduce its dependence on foreign sources of oil.
September 11 2013
Speakers will provide fresh insight, investment opportunities in biotech sector.
July 10 2013
Chimerix President and CEO emphasizes the role of the public market to help finance critical R&D.
June 14 2012
Support Of Industry Underscores Pro-Business Commitment
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."